MedTrace Logo

REvision of VSG with Ablation of the Mucosa Procedure

NCT06671119 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-11-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the feasibility, safety, and tolerability of endoscopic selective gastric mucosal ablation (GMA) using argon plasma coagulation after sleeve gastrectomy. In this study, GMA will be performed on patients who have experienced weight regain following an initial successful response to sleeve gastrectomy.

Conditions

  • Obesity and Obesity-related Medical Conditions
  • Obesity and Overweight
  • Obesity Prevention
  • Obesity Recidivism

Interventions

DEVICE

Gastric Mucosal Ablation (GMA)

Endoscopic Gastric Mucosal Ablation (GMA) after sleeve gastrectomy

Sponsors & Collaborators

  • Dr. Christopher McGowan

    lead OTHER

Principal Investigators

  • Christopher McGowan, MD, MSCR · True You Weight Loss

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-31
Primary Completion
2026-05-31
Completion
2026-05-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06671119 on ClinicalTrials.gov